Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001‐2011)

Strotman, Patrick K.; Reif, Taylor J.; Kliethermes, Stephanie; Sandhu, Jasmin; Nystrom, Lukas M.

doi:10.1002/jso.24650

Cited by 77 publications

(85 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our aim was to find pre‐treatment serum markers as independent factors for estimation of survival in chondrosarcoma patients. Several prognostic factors have been described in previous reports: Pelvic location, increased age, metastasis at diagnosis,4 pathological fracture,13 advanced tumor stage (AJCC III or IV), and size (tumors larger than 8 cm)2 and inadequate resection margins 14…”

Section: Discussionmentioning

confidence: 97%

“…The state of the art treatment consists of the wide resection of the tumor. Survival rates did not improve over the last decades despite aggressive resection, systemic treatment with chemotherapy and advanced diagnostic techniques 2. Our aim was to find pre‐treatment serum markers as independent factors for estimation of survival in chondrosarcoma patients.…”

Section: Discussionmentioning

confidence: 99%

“…First described by Dahlin and Bebout in 1971,1 it is characterized by high‐grade, non‐cartilaginous sarcoma adjacent to a low‐grade or intermediate chondrosarcoma and makes about 10% of all chondrosarcomas 2…”

mentioning

confidence: 99%

“…The surgical resection with wide or radical margins is considered as standard and most important therapy option, though the prognosis is poor with 5‐year survival rates mostly under 20% 2. The National Comprehensive Cancer Network guidelines suggest that the dedifferentiated chondrosarcoma should be treated like the osteosarcoma 3…”

mentioning

confidence: 99%

“…For risk estimation, several prognostic markers such as location, pathologic fracture, age > 60, size, metastasis at diagnosis, have been described previously 2, 4…”

mentioning

confidence: 99%

See 4 more Smart Citations

C‐reactive protein: An independent predictor for dedifferentiated chondrosarcoma

Nemecek

Funovics

Hobusch

et al. 2018

Journal Orthopaedic Research

View full text Add to dashboard Cite

Dedifferentiated chondrosarcoma is a rare primary bone malignancy with a very poor prognosis. The aim of the study was to identify pretreatment serum markers as prognostic factors for the overall survival (OS) of patients with dedifferentiated chondrosarcoma. We retrospectively reviewed 33 patients with histologically confirmed dedifferentiated chondrosarcoma treated at our department from 1977 to 2015. Kaplan‐Meier estimation, uni‐ and multivariable Cox proportional hazard model were performed to evaluate the association between serum markers such as the C‐reactive protein and OS. In univariable analysis, CRP was strongly associated with OS (HR 1.35; 95%CI 1.13–1.61; p = 0.001). This association prevailed after adjustment for AJCC tumor stage (HR 1.31; 95%CI 1.02–1.57; p = 0.031) in multivariable analysis. In conclusion, our data gave evidence that baseline CRP is an independent predictor for OS in patients with dedifferentiated chondrosarcoma. CRP could be exploited for the clinical prediction of this disease in the future. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 36:2797–2801, 2018.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

“…For risk estimation, several prognostic markers such as location, pathologic fracture, age > 60, size, metastasis at diagnosis, have been described previously 2, 4…”

mentioning

confidence: 99%

See 3 more Smart Citations

C‐reactive protein: An independent predictor for dedifferentiated chondrosarcoma

Nemecek

Funovics

Hobusch

et al. 2018

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations

et al. 2021

View full text Add to dashboard Cite

Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable, and more objective biomarkers are required. We aimed to determine whether the level of circulating tumour DNA (ctDNA) in the blood of CS patients could be used to predict outcome. In this multi-institutional study, we recruited 145 patients with cartilaginous tumours, of which 41 were excluded. ctDNA levels were assessed in 83 of the remaining 104 patients, whose tumours harboured a hotspot mutation in IDH1/2 or GNAS. ctDNA was detected pre-operatively in 31/83 (37%) and in 12/31 (39%) patients postoperatively. We found that detection of ctDNA was more accurate than pathology for identification of high-grade tumours and was associated with a poor prognosis; ctDNA was never associated with CS grade 1/atypical cartilaginous tumours (ACT) in the long bones, in neoplasms sited in the small bones of the hands and feet or in tumours measuring less than 80 mm. Although the results are promising, they are based on a small number of patients, and therefore, introduction of this blood test into clinical practice as a complementary assay to current standard-of-care protocols would allow the assay to be assessed more stringently and developed for a more personalised approach for the treatment of patients with CS.

show abstract

Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis

Amer

Munn

Congiusta

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Chondrosarcomas are rare tumors and, historically, investigation of these tumors has been limited to small series and single-institution studies. There have been no studies that evaluated the identification or comparison of differences in prognostic factors between the five known non-conventional chondrosarcoma subtypes (myxoid, juxtacortical, clear-cell, mesenchymal, and dedifferentiated). The purpose of this paper was to determine the demographic, clinical, incidence, and tumor characteristics of all five known non-conventional chondrosarcoma subtypes, determine the 1-, 5-year, and median survival differences between these subtypes, and to determine the demographic and clinical variables that are significant prognostic indicators for each chondrosarcoma subtypes. We retrospectively reviewed the SEER database for all patients with non-conventional chondrosarcoma. χ 2 testing was used for correlations between clinical variables. Kaplan-Meier and Cox proportional hazard analysis were used to compare survival of the subtypes, and to assess the prognostic value of age group, race, sex, grade, anatomic location, and metastatic involvement. Several demographic characteristics including gender, race, age, and grade varied between chondrosarcoma subtypes. The tumor characteristics showed marked differences in presence of metastasis on presentation between the subtypes with increasing order of rate of metastasis with juxtacortical (2.1%), clear cell (5.7%), myxoid (7.6%), mesenchymal (10.6%), and the highest in dedifferentiated (19.8%). One-, 5-year, and median survival differed significantly between chondrosarcomas subtypes. The highest median survival was found in the juxtacortical subtype (97 months), followed by clear cell (79 months), myxoid (60 months), mesenchymal (33.5 months), and lowest in dedifferentiated (11 months). The only prognostic variable that was shown to significantly impact the survival of each non-conventional chondrosarcoma subtype was a metastatic disease at diagnosis (p = 0.03 to p < 0.001). Subtyping classification of chondrosarcoma should be made whenever possible, given differences in survival and prognostic factors between chondrosarcoma subtypes.

show abstract

Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001‐2011)

Cited by 77 publications

References 25 publications

C‐reactive protein: An independent predictor for dedifferentiated chondrosarcoma

C‐reactive protein: An independent predictor for dedifferentiated chondrosarcoma

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations

Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis

Contact Info

Product

Resources

About